Skip to main content

View Resource

Published

Integrated virologic analysis of resistance to nirmatrelvir/ritonavir in individuals across four phase 2/3 clinical studies for the treatment of COVID-19.
Baniecki ML. eBioMedicine 2025;:https://doi.org/10.1016/j.ebiom.2025.105819.
[SARS-CoV-2 resistance to nirmatrelvir/ritonavir (NMV/r) surveillance is essential to identify emergence and track treatment-resistance. In EPIC, NMV-resistance mutations were infrequent. E166V was the only resistance-associated substitution but was not identified in participants experiencing hospitalisation or with immunocompromising conditions. NCT04960202, NCT05011513, NCT05438602, NCT05567952.]
Freely available online
Age Groups
Adults
Conditions and Lifestyle Factors
Antibiotic Resistance
Coronavirus Infections
Settings
Hospital Ward
Intensive Care
Staff Groups
Drug Therapy